Teva’s Patent for Copaxone Upheld by New York Federal Court

U.S. District Judge Barbara Jones in Manhattan today ruled that drug applications by Sandoz and Mylan for generic versions of TEVA’s patented drug, Copaxone, a pharmaceutical treatment for multiple sclerosis medicine “infringe all of the asserted claims.”

Teva sued Basel, Switzerland-based Novartis and Cambridge, Massachusetts-based Momenta, saying that copies of Copaxone would infringe four patents that expire in 2014.

The Federal Judge has now ruled that the infringed claims are valid and enforceable.

Momenta, a further company attempting to bring a generic version of the product to market was not mentioned in the ruling.

The case is Teva Pharmaceuticals USA Inc. v. Sandoz Inc., 08-cv-07611, U.S. District Court, Southern District of New York (Manhattan).

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: